Results 201 to 210 of about 4,757,713 (278)
Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet. [PDF]
Kounatidis D +9 more
europepmc +1 more source
Post‐COVID Fatigue Is Associated With Reduced Cortical Thickness After Hospitalization
ABSTRACT Objective Neuropsychiatric symptoms are among the most prevalent sequelae of COVID‐19, particularly among hospitalized patients. Recent research has identified volumetric brain changes associated with COVID‐19. However, it currently remains poorly understood how brain changes relate to post‐COVID fatigue and cognitive deficits.
Tim J. Hartung +190 more
wiley +1 more source
Wearable Devices in Elderly Chronic Disease Management: A Qualitative Study of Barriers and Facilitators. [PDF]
Zhang H, Xu J, Lu X, Xu M.
europepmc +1 more source
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo +9 more
wiley +1 more source
Improving Parkinson's disease management through wearable technology: A cost-benefit perspective. [PDF]
Rodriguez-Martin D +2 more
europepmc +1 more source
Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study
ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang +7 more
wiley +1 more source
Scavenging of reactive oxygen and nitrogen species using nanoparticles and their applications in disease management. [PDF]
Rananaware P, Singh S, Brahmkhatri VP.
europepmc +1 more source
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang +8 more
wiley +1 more source

